| Registrars: | Equiniti |
| Brands: | Lucozade, Horlicks, Ribena, Paxil, Seroxat |
| CEO: | Emma Walmsley |
| Chief Finance Officer: | Julie Brown |
| Independent Non-Executive Director: | Harry (Hal) C. Dietz |
| Independent Non-Executive Director: | Vishal Sikka |
| Independent Non-Executive Director: | Elizabeth (Liz) McKee Anderson |
| Independent Non-Executive Director: | Anne Beal |
| Non-Executive Chairman: | Jonathan Symonds |
| Senior Independent Non-Executive Director: | Charles Bancroft |
| Non-Executive Dir: | Wendy Becker , Jeannie Lee , Hal Barron , Gavin Screaton |
| Address: | 79 New Oxford Street, London, United Kingdom, WC1A 1DG |
| Phone: | +44 (0)20 8047 5000 |
| Website: | http://www.gsk.com/en-gb/ |
| Sector: | Pharma and Biotech(LSE) |
| Index: | techMARK, FTSE 100, FTSE 350, FTSE All-Share |
| Overseas Listings: | BATSLON:GSKL, NYSE:GSK |
| ISIN: | GB00BN7SWP63 |
| Currency | UK Pounds |
| Share Price | 1,805.00p |
| Change Today | -21.00p |
| % Change | -1.15 % |
| 52 Week High | 1,833.50p |
| 52 Week Low | 1,264.00p |
| Volume | 4,275,227 |
| Shares Issued | 4,077.97m |
| Market Cap | £73,607m |
| RiskGrade | 129 |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Strong Buy | 4 |
| Buy | 3 |
| Neutral | 14 |
| Sell | 2 |
| Strong Sell | 0 |
| Total | 23 |

| Latest | Previous | |
|---|---|---|
| Q3 | Q2 | |
| Ex-Div | 13-Nov-25 | 14-Aug-25 |
| Paid | 08-Jan-26 | 09-Oct-25 |
| Amount | 16.00p | 16.00p |
| Time | Volume / Share Price |
| 16:06 | 2 @ 1,800.00p |
| 15:35 | 0 @ 1,801.50p |
| 16:48 | 3,476 @ 1,805.00p |
| 16:48 | 426 @ 1,805.00p |
| 16:47 | 34,254 @ 1,814.13p |
You are here: research